Control Bionics Lands First US Customer With $100K Upfront and $2.5M+ Revenue Path
Control Bionics (ASX: CBL) has signed its first Letter of Intent with a U.S. customer for its Control Bionics iOS Speech Device program, marking the first commercial validation of the company’s recently announced partnership with NextLevel. The customer has made an advance payment of US$100,000 and expects to generate annual revenue of US$2.5-3.5 million for CBL once supply commences towards the end of FY26.
Control Bionics signs first U.S. customer commitment for iOS speech device program
The neurotechnology and assistive communication solutions provider announced on 26 March 2026 that it has executed a non-binding LOI with a United States customer following its NextLevel partnership. The agreement outlines the customer’s intention to acquire a significant number of iOS-based speech generating devices annually once commercial supply begins.
The US$100,000 advance payment demonstrates tangible market interest and will be credited pro-rata against the purchase price of the first 1,000 devices supplied under the program. Shipments are expected to commence towards the end of FY26, subject to final commercial agreements and operational readiness.
This LOI represents the first commercial traction from Control Bionics’ strategy to expand into iOS-based speech generating devices. The collaboration with NextLevel enables the company to leverage its existing expertise in assistive communication and distribution-led commercialisation to address the growing U.S. market for Apple iOS-based speech generating devices (SGDs).
For investors, this milestone signals that the NextLevel partnership strategy is gaining real-world momentum beyond the initial announcement phase. The advance payment provides near-term cash flow and de-risks the partnership by demonstrating buyer commitment before supply begins.
When big ASX news breaks, our subscribers know first
What are iOS-based speech generating devices?
Speech generating devices are assistive technology products designed to help individuals with communication impairments express themselves. These devices produce spoken communication for people who are unable to speak or have difficulty speaking due to conditions such as motor neurone disease, cerebral palsy, or stroke.
Traditional SGDs were standalone, dedicated hardware units. However, the market is shifting towards tablet-based solutions, particularly those using Apple’s iOS platform. These iOS-based devices combine familiar tablet interfaces with specialised communication software, offering greater flexibility and user acceptance.
Control Bionics’ approach builds on its established expertise in assistive communication technology, including its patented NeuroNode technology which detects signals sent from the brain to skeletal muscles. This expertise positions the company to deliver iOS-based SGDs that integrate multiple control modalities for enhanced user experience.
The U.S. market for iOS-based SGDs is supported by established reimbursement pathways, reducing revenue uncertainty for providers. Growing clinician and user preference for tablet-based communication solutions further validates the commercial opportunity Control Bionics is pursuing.
Deal structure and commercial terms
The Letter of Intent establishes a framework for commercial supply of Control Bionics iOS Speech Device units, though the agreement remains non-binding pending finalisation of definitive supply arrangements. The customer’s advance payment provides tangible validation of market demand while supporting Control Bionics’ continued investment in bringing these solutions to market.
| Term | Detail | Status | Timeline |
|---|---|---|---|
| Letter of Intent | First U.S. customer commitment | Signed (non-binding) | 26 March 2026 |
| Advance Payment | US$100,000 | Received | Immediate |
| Annual Device Volume | Significant (unspecified) | Subject to final agreement | Ongoing |
| Projected Annual Revenue | US$2.5-3.5 million | Upon commercial supply | End FY26 onwards |
| Credit Terms | Advance credited against first 1,000 devices | Pro-rata application | Upon supply commencement |
The advance payment mechanism reduces execution risk by providing Control Bionics with upfront capital while the customer secures future supply pricing. The pro-rata credit structure against the first 1,000 devices creates a clear path to converting the LOI into sustained commercial activity.
CEO commentary
Jeremy Steele, CEO and Managing Director
“This Letter of Intent is an important early milestone following our partnership with NextLevel and demonstrates strong interest from US providers in Control Bionics’ iOS-based speech device strategy. The advance payment from the customer provides tangible validation of market demand and supports our continued investment in bringing these solutions to market.”
U.S. market opportunity and strategic rationale
The U.S. market for iOS-based speech generating devices represents a significant growth opportunity for Control Bionics, underpinned by established reimbursement pathways that support commercial viability. Unlike many emerging medical technology markets where reimbursement remains uncertain, the U.S. SGD market benefits from existing coverage frameworks that facilitate customer adoption and recurring revenue streams.
Increasing clinician and user preference for tablet-based communication solutions strengthens the commercial case for Control Bionics’ iOS-focused strategy. Tablet platforms offer familiar interfaces, regular software updates, and ecosystem compatibility that traditional dedicated devices cannot match. This preference shift creates a natural replacement cycle as older dedicated SGD units reach end-of-life.
The partnership with NextLevel enables Control Bionics to deploy its distribution-led commercialisation approach in the U.S. market. This model leverages existing distribution channels and customer relationships rather than requiring Control Bionics to build direct sales infrastructure from scratch, accelerating time-to-market and reducing upfront capital requirements.
For investors, the established reimbursement environment reduces revenue uncertainty compared to unproven markets. The recurring annual device volume outlined in the LOI suggests potential for predictable revenue streams rather than one-off sales, supporting more stable financial performance once commercial supply commences.
The next major ASX story will hit our subscribers first
What comes next for Control Bionics
Control Bionics will now work with the customer to finalise a definitive supply agreement, converting the non-binding LOI into binding commercial terms. The company has stated it will update the market as further milestones are achieved, providing investors with visibility on the progression from LOI to active revenue generation.
The key steps ahead include:
- Finalise definitive supply agreement with the U.S. customer
- Achieve operational readiness for commercial supply
- Commence shipments towards end of FY26
- Pursue additional LOIs with other U.S. providers
The expected shipment commencement towards the end of FY26 provides investors with a clear near-term catalyst to track. This timeline falls within the April to June 2026 period, suggesting potential revenue recognition in the final quarter of the current financial year.
The company’s stated intention to pursue additional LOIs indicates this first customer commitment represents an initial proof point rather than an isolated transaction. Success in converting this LOI to active supply could support a broader rollout across multiple U.S. providers, scaling the US$2.5-3.5 million annual revenue opportunity established with this first customer.
For Control Bionics shareholders, the advance payment provides immediate cash flow while the longer-term revenue potential creates a measurable milestone against which to assess the NextLevel partnership’s commercial effectiveness. The combination of near-term cash and medium-term recurring revenue opportunity addresses both liquidity and growth objectives.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to receive market-moving announcements the moment they hit the ASX, analysed and ready to act on.